| Number of patients without NSTEMI as proportion of total . | Algorithm . | False positive . | True negative (change from baseline) . | False negative . | Relative change in true negative rate . |
|---|---|---|---|---|---|
| Patients presenting >3 h from symptom onset 660/750 | Hs-cTnT < 5 ng/L | 435 | 225 (0) | 1 | 1.00 comparator |
| Hs-cTnT < 7 ng/L | 302 | 358 (+133) | 1 | 1.59 | |
| Hs-cTnT < 7 ng/L and copeptin < 9 pmol/L | 341 | 319 (+94) | 1 | 1.42 | |
| Hs-cTnT < 7 ng/L and glucose < 5.6 mmol/L | 482 | 178 (-47) | 1 | 0.79 | |
| Hs-cTnI < 4 ng/L | 290 | 370 (0) | 2 | 1.00 comparator | |
| Hs-cTnI < 7 ng/L | 170 | 490 (+120) | 4 | 1.32 | |
| Hs-cTnI < 7 ng/L and copeptin < 9 pmol/L | 245 | 415 (+45) | 2 | 1.12 | |
| Hs-cTnI < 7 ng/L and glucose < 5.6 mmol/L | 427 | 233 (−137) | 1 | 0.63 | |
| All patients 834/959 | Hs-cTnT < 5 ng/L | 544 | 290 | 2 | 1.00 comparator |
| Hs-cTnT < 7 ng/L | 383 | 451 (+161) | 3 | 1.56 | |
| Hs-cTnT < 7 ng/L and copeptin < 9 pmol/L | 442 | 392 (+102) | 1 | 1.35 | |
| Hs-cTnT < 7 ng/L and glucose < 5.6 mmol/L | 620 | 214 (-76) | 2 | 0.74 | |
| Hs-cTnI < 4 ng/L | 365 | 469 (0) | 5 | 1.00 comparator | |
| Hs-cTnI < 7 ng/L | 220 | 614 (+145) | 8 | 1.31 | |
| Hs-cTnI < 7 ng/L and copeptin < 9 pmol/L | 327 | 507 (+38) | 3 | 1.08 | |
| Hs-cTnI < 7 ng/L and glucose < 5.6 mmol/L | 558 | 276 (−190) | 2 | 0.59 |
| Number of patients without NSTEMI as proportion of total . | Algorithm . | False positive . | True negative (change from baseline) . | False negative . | Relative change in true negative rate . |
|---|---|---|---|---|---|
| Patients presenting >3 h from symptom onset 660/750 | Hs-cTnT < 5 ng/L | 435 | 225 (0) | 1 | 1.00 comparator |
| Hs-cTnT < 7 ng/L | 302 | 358 (+133) | 1 | 1.59 | |
| Hs-cTnT < 7 ng/L and copeptin < 9 pmol/L | 341 | 319 (+94) | 1 | 1.42 | |
| Hs-cTnT < 7 ng/L and glucose < 5.6 mmol/L | 482 | 178 (-47) | 1 | 0.79 | |
| Hs-cTnI < 4 ng/L | 290 | 370 (0) | 2 | 1.00 comparator | |
| Hs-cTnI < 7 ng/L | 170 | 490 (+120) | 4 | 1.32 | |
| Hs-cTnI < 7 ng/L and copeptin < 9 pmol/L | 245 | 415 (+45) | 2 | 1.12 | |
| Hs-cTnI < 7 ng/L and glucose < 5.6 mmol/L | 427 | 233 (−137) | 1 | 0.63 | |
| All patients 834/959 | Hs-cTnT < 5 ng/L | 544 | 290 | 2 | 1.00 comparator |
| Hs-cTnT < 7 ng/L | 383 | 451 (+161) | 3 | 1.56 | |
| Hs-cTnT < 7 ng/L and copeptin < 9 pmol/L | 442 | 392 (+102) | 1 | 1.35 | |
| Hs-cTnT < 7 ng/L and glucose < 5.6 mmol/L | 620 | 214 (-76) | 2 | 0.74 | |
| Hs-cTnI < 4 ng/L | 365 | 469 (0) | 5 | 1.00 comparator | |
| Hs-cTnI < 7 ng/L | 220 | 614 (+145) | 8 | 1.31 | |
| Hs-cTnI < 7 ng/L and copeptin < 9 pmol/L | 327 | 507 (+38) | 3 | 1.08 | |
| Hs-cTnI < 7 ng/L and glucose < 5.6 mmol/L | 558 | 276 (−190) | 2 | 0.59 |
Number of false positives, true negatives, and the changes in the true negative rate for selected algorithms in patients presenting >3 h from symptom onset and all patients. Data from the Norwegian cohort.
| Number of patients without NSTEMI as proportion of total . | Algorithm . | False positive . | True negative (change from baseline) . | False negative . | Relative change in true negative rate . |
|---|---|---|---|---|---|
| Patients presenting >3 h from symptom onset 660/750 | Hs-cTnT < 5 ng/L | 435 | 225 (0) | 1 | 1.00 comparator |
| Hs-cTnT < 7 ng/L | 302 | 358 (+133) | 1 | 1.59 | |
| Hs-cTnT < 7 ng/L and copeptin < 9 pmol/L | 341 | 319 (+94) | 1 | 1.42 | |
| Hs-cTnT < 7 ng/L and glucose < 5.6 mmol/L | 482 | 178 (-47) | 1 | 0.79 | |
| Hs-cTnI < 4 ng/L | 290 | 370 (0) | 2 | 1.00 comparator | |
| Hs-cTnI < 7 ng/L | 170 | 490 (+120) | 4 | 1.32 | |
| Hs-cTnI < 7 ng/L and copeptin < 9 pmol/L | 245 | 415 (+45) | 2 | 1.12 | |
| Hs-cTnI < 7 ng/L and glucose < 5.6 mmol/L | 427 | 233 (−137) | 1 | 0.63 | |
| All patients 834/959 | Hs-cTnT < 5 ng/L | 544 | 290 | 2 | 1.00 comparator |
| Hs-cTnT < 7 ng/L | 383 | 451 (+161) | 3 | 1.56 | |
| Hs-cTnT < 7 ng/L and copeptin < 9 pmol/L | 442 | 392 (+102) | 1 | 1.35 | |
| Hs-cTnT < 7 ng/L and glucose < 5.6 mmol/L | 620 | 214 (-76) | 2 | 0.74 | |
| Hs-cTnI < 4 ng/L | 365 | 469 (0) | 5 | 1.00 comparator | |
| Hs-cTnI < 7 ng/L | 220 | 614 (+145) | 8 | 1.31 | |
| Hs-cTnI < 7 ng/L and copeptin < 9 pmol/L | 327 | 507 (+38) | 3 | 1.08 | |
| Hs-cTnI < 7 ng/L and glucose < 5.6 mmol/L | 558 | 276 (−190) | 2 | 0.59 |
| Number of patients without NSTEMI as proportion of total . | Algorithm . | False positive . | True negative (change from baseline) . | False negative . | Relative change in true negative rate . |
|---|---|---|---|---|---|
| Patients presenting >3 h from symptom onset 660/750 | Hs-cTnT < 5 ng/L | 435 | 225 (0) | 1 | 1.00 comparator |
| Hs-cTnT < 7 ng/L | 302 | 358 (+133) | 1 | 1.59 | |
| Hs-cTnT < 7 ng/L and copeptin < 9 pmol/L | 341 | 319 (+94) | 1 | 1.42 | |
| Hs-cTnT < 7 ng/L and glucose < 5.6 mmol/L | 482 | 178 (-47) | 1 | 0.79 | |
| Hs-cTnI < 4 ng/L | 290 | 370 (0) | 2 | 1.00 comparator | |
| Hs-cTnI < 7 ng/L | 170 | 490 (+120) | 4 | 1.32 | |
| Hs-cTnI < 7 ng/L and copeptin < 9 pmol/L | 245 | 415 (+45) | 2 | 1.12 | |
| Hs-cTnI < 7 ng/L and glucose < 5.6 mmol/L | 427 | 233 (−137) | 1 | 0.63 | |
| All patients 834/959 | Hs-cTnT < 5 ng/L | 544 | 290 | 2 | 1.00 comparator |
| Hs-cTnT < 7 ng/L | 383 | 451 (+161) | 3 | 1.56 | |
| Hs-cTnT < 7 ng/L and copeptin < 9 pmol/L | 442 | 392 (+102) | 1 | 1.35 | |
| Hs-cTnT < 7 ng/L and glucose < 5.6 mmol/L | 620 | 214 (-76) | 2 | 0.74 | |
| Hs-cTnI < 4 ng/L | 365 | 469 (0) | 5 | 1.00 comparator | |
| Hs-cTnI < 7 ng/L | 220 | 614 (+145) | 8 | 1.31 | |
| Hs-cTnI < 7 ng/L and copeptin < 9 pmol/L | 327 | 507 (+38) | 3 | 1.08 | |
| Hs-cTnI < 7 ng/L and glucose < 5.6 mmol/L | 558 | 276 (−190) | 2 | 0.59 |
Number of false positives, true negatives, and the changes in the true negative rate for selected algorithms in patients presenting >3 h from symptom onset and all patients. Data from the Norwegian cohort.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
